Metabolism of plasma low density lipoproteins in familial combined hyperlipidaemia: Effect of acipimox therapy

S. Ericsson, M. Eriksson, Lars Berglund, B. Angelin

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Ten male patients with familial combined hyperlipidaemia (FCHL) were studied with regard to LDL metabolism and composition. The FCHL patients had higher LDL levels than healthy controls (5.4 ± 1.4 vs. 3.7 ± 0.7 mmol l-1; P < 0.005) and a higher rate of production of the lipoprotein (15.8 ± 3.1 mg kg-1 d-1 in FCHL vs. 13.1 ± 1.8 mg kg-1 d-1 in the normals; P < 0.005). The fractional catabolic rate of LDL was low-normal in the FCHL patients, with a high level of interindividual variation. The actual individual LDL cholesterol level within the FCHL patient group appeared to be more closely associated with the LDL apoB FCR value than the rate of production of the particle. Analysis of the LDL particles from FCHL patients revealed a relative enrichment in triglycerides, while the cholesterol content of the lipoprotein was normal. Institution of acipimox therapy in 8 patients reversed the high rate of synthesis of LDL (15.2 ± 3.5 mg kg-1 d-1) to a more normal level (13.9 ± 4.0 mg kg-1 d-1; P = 0.08), while the FCR did not change significantly. In conclusion, patients with FCHL show an apparent overproduction of LDL apoB, while the actual degree of LDL elevation appeas to be dependent on the clearance capacity of the lipoprotein, measured as LDL apoB FCR. The overproduction defect of LDL apoB can, at least in part, be managed by treatment with the nicotinic acid analogue acipimox.

Original languageEnglish (US)
Pages (from-to)313-320
Number of pages8
JournalJournal of Internal Medicine
Volume232
Issue number4
StatePublished - 1992
Externally publishedYes

Fingerprint

Familial Combined Hyperlipidemia
LDL Lipoproteins
Apolipoproteins B
Therapeutics
Lipoproteins
acipimox
oxidized low density lipoprotein
Niacin
LDL Cholesterol
Triglycerides

Keywords

  • Acipimox
  • Cholesterol
  • Familial combined hyperlipidaemia
  • Low density lipoproteins
  • Triglycerides

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Metabolism of plasma low density lipoproteins in familial combined hyperlipidaemia : Effect of acipimox therapy. / Ericsson, S.; Eriksson, M.; Berglund, Lars; Angelin, B.

In: Journal of Internal Medicine, Vol. 232, No. 4, 1992, p. 313-320.

Research output: Contribution to journalArticle

@article{9e7b2d0620384e8787d4dd1f2a3cac2a,
title = "Metabolism of plasma low density lipoproteins in familial combined hyperlipidaemia: Effect of acipimox therapy",
abstract = "Ten male patients with familial combined hyperlipidaemia (FCHL) were studied with regard to LDL metabolism and composition. The FCHL patients had higher LDL levels than healthy controls (5.4 ± 1.4 vs. 3.7 ± 0.7 mmol l-1; P < 0.005) and a higher rate of production of the lipoprotein (15.8 ± 3.1 mg kg-1 d-1 in FCHL vs. 13.1 ± 1.8 mg kg-1 d-1 in the normals; P < 0.005). The fractional catabolic rate of LDL was low-normal in the FCHL patients, with a high level of interindividual variation. The actual individual LDL cholesterol level within the FCHL patient group appeared to be more closely associated with the LDL apoB FCR value than the rate of production of the particle. Analysis of the LDL particles from FCHL patients revealed a relative enrichment in triglycerides, while the cholesterol content of the lipoprotein was normal. Institution of acipimox therapy in 8 patients reversed the high rate of synthesis of LDL (15.2 ± 3.5 mg kg-1 d-1) to a more normal level (13.9 ± 4.0 mg kg-1 d-1; P = 0.08), while the FCR did not change significantly. In conclusion, patients with FCHL show an apparent overproduction of LDL apoB, while the actual degree of LDL elevation appeas to be dependent on the clearance capacity of the lipoprotein, measured as LDL apoB FCR. The overproduction defect of LDL apoB can, at least in part, be managed by treatment with the nicotinic acid analogue acipimox.",
keywords = "Acipimox, Cholesterol, Familial combined hyperlipidaemia, Low density lipoproteins, Triglycerides",
author = "S. Ericsson and M. Eriksson and Lars Berglund and B. Angelin",
year = "1992",
language = "English (US)",
volume = "232",
pages = "313--320",
journal = "Journal of Internal Medicine",
issn = "0954-6820",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Metabolism of plasma low density lipoproteins in familial combined hyperlipidaemia

T2 - Effect of acipimox therapy

AU - Ericsson, S.

AU - Eriksson, M.

AU - Berglund, Lars

AU - Angelin, B.

PY - 1992

Y1 - 1992

N2 - Ten male patients with familial combined hyperlipidaemia (FCHL) were studied with regard to LDL metabolism and composition. The FCHL patients had higher LDL levels than healthy controls (5.4 ± 1.4 vs. 3.7 ± 0.7 mmol l-1; P < 0.005) and a higher rate of production of the lipoprotein (15.8 ± 3.1 mg kg-1 d-1 in FCHL vs. 13.1 ± 1.8 mg kg-1 d-1 in the normals; P < 0.005). The fractional catabolic rate of LDL was low-normal in the FCHL patients, with a high level of interindividual variation. The actual individual LDL cholesterol level within the FCHL patient group appeared to be more closely associated with the LDL apoB FCR value than the rate of production of the particle. Analysis of the LDL particles from FCHL patients revealed a relative enrichment in triglycerides, while the cholesterol content of the lipoprotein was normal. Institution of acipimox therapy in 8 patients reversed the high rate of synthesis of LDL (15.2 ± 3.5 mg kg-1 d-1) to a more normal level (13.9 ± 4.0 mg kg-1 d-1; P = 0.08), while the FCR did not change significantly. In conclusion, patients with FCHL show an apparent overproduction of LDL apoB, while the actual degree of LDL elevation appeas to be dependent on the clearance capacity of the lipoprotein, measured as LDL apoB FCR. The overproduction defect of LDL apoB can, at least in part, be managed by treatment with the nicotinic acid analogue acipimox.

AB - Ten male patients with familial combined hyperlipidaemia (FCHL) were studied with regard to LDL metabolism and composition. The FCHL patients had higher LDL levels than healthy controls (5.4 ± 1.4 vs. 3.7 ± 0.7 mmol l-1; P < 0.005) and a higher rate of production of the lipoprotein (15.8 ± 3.1 mg kg-1 d-1 in FCHL vs. 13.1 ± 1.8 mg kg-1 d-1 in the normals; P < 0.005). The fractional catabolic rate of LDL was low-normal in the FCHL patients, with a high level of interindividual variation. The actual individual LDL cholesterol level within the FCHL patient group appeared to be more closely associated with the LDL apoB FCR value than the rate of production of the particle. Analysis of the LDL particles from FCHL patients revealed a relative enrichment in triglycerides, while the cholesterol content of the lipoprotein was normal. Institution of acipimox therapy in 8 patients reversed the high rate of synthesis of LDL (15.2 ± 3.5 mg kg-1 d-1) to a more normal level (13.9 ± 4.0 mg kg-1 d-1; P = 0.08), while the FCR did not change significantly. In conclusion, patients with FCHL show an apparent overproduction of LDL apoB, while the actual degree of LDL elevation appeas to be dependent on the clearance capacity of the lipoprotein, measured as LDL apoB FCR. The overproduction defect of LDL apoB can, at least in part, be managed by treatment with the nicotinic acid analogue acipimox.

KW - Acipimox

KW - Cholesterol

KW - Familial combined hyperlipidaemia

KW - Low density lipoproteins

KW - Triglycerides

UR - http://www.scopus.com/inward/record.url?scp=0026730609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026730609&partnerID=8YFLogxK

M3 - Article

C2 - 1402634

AN - SCOPUS:0026730609

VL - 232

SP - 313

EP - 320

JO - Journal of Internal Medicine

JF - Journal of Internal Medicine

SN - 0954-6820

IS - 4

ER -